toxicities associated with anti–pd-1 immunotherapy
Published 7 years ago • 1.5K plays • Length 11:40Download video MP4
Download video MP3
Similar videos
-
4:33
overall toxicities with immunotherapy in melanoma
-
4:22
immunotherapy-related pulmonary toxicities in melanoma
-
4:32
overall toxicities with immunotherapy in melanoma
-
1:13
dr. jedd wolchok on immunotherapy toxicities
-
6:31
managing immunotherapy-related toxicity
-
4:21
immunotherapy-related pulmonary toxicities in melanoma
-
42:23
managing adverse events associated with immuno-oncologic agents | dr. igor puzanov
-
4:29
anti–pd-1 therapy in metastatic melanoma
-
6:12
immunotherapy toxicity management in nsclc
-
1:21
dr. julie brahmer on the pd-1 targeted immunotherapy bms-93655 clinical trial
-
0:51
monitor toxicities when treating breast cancer with immunotherapy
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
6:03
immunotherapy: toxicity, pseudo-progression, and varied responses
-
3:36
anti-pd-l1 immunotherapy with mpdl3280a in metastatic bladder cancer
-
6:44
immunotherapy toxicity management in bladder cancer
-
0:59
dr. martins on managing toxicities associated with lenvatinib in dtc
-
8:56
managing toxicity of immunotherapy in melanoma
-
8:01
anti–pd-1 adjuvant therapy in melanoma
-
7:25
how to manage toxicities from immune checkpoint inhibitors?